For Golden Triangle sequencing, proteomics, spatial and diagnostics companies: pre-scheduled 1:1 meetings with pharma biomarker teams in London on 3–4 March 2027, under an hour by train.
Sponsor London 2027
Our sponsorship team replies within one working day.
Trusted by sponsors from our London 2026 launch edition




Our London 2026 sponsors came from five kinds of company, and the Biomarkers & CDx stream adds a sixth. If yours is on this list, the agenda is built around your buyers.
Biomarker testing, flow cytometry and assay services for clinical trials.
Who you meet: Translational medicine and clinical biomarker leads

In vivo models and antibody discovery for immuno-oncology pipelines.
Who you meet: Discovery, pharmacology and preclinical heads
Instruments, reagents and platforms for immune profiling and proteomics.
Who you meet: Immune monitoring and translational science teams

Functional and spatial readouts from patient tissue.
Who you meet: Pathology and biomarker discovery leads
Data, literature and analytics for R&D and competitive intelligence.
Who you meet: R&D strategy and data science teams
The Biomarkers & CDx stream covers CDx development, regulatory strategy and market access.
Who you meet: Pharma CDx, regulatory and medical diagnostics leads
Tell us which roles you need to meet and we will show you how the audience matches up.
Request the prospectusIf your company sells sequencing, epigenetic, proteomic, spatial or diagnostic technology from Cambridge, Oxford, Stevenage or Harwell, the London edition of ImmunoMark Summit on 3–4 March 2027 puts pharma and biotech biomarker teams in front of you without a flight or a hotel block.
The 2nd annual UK edition expects 400+ delegates across two parallel streams: Stream 1, Next-Gen Immuno-Oncology, and Stream 2, Biomarkers & Companion Diagnostics. For most Golden Triangle tools and diagnostics companies, Stream 2 is where the buyers sit. The prospectus profiles them as Heads and Directors of Translational Medicine, Biomarker Operations Leads, Principal Scientists and teams in Biomarker Discovery & Development, Companion Diagnostics and Bioinformatics / Data Science.
Every part of the cluster has a direct rail line into a London terminus, so you can staff a stand on day trips rather than overnight stays.
| From | Main rail route | Fastest timetabled journey |
|---|---|---|
| Cambridge (Cambridge or Cambridge North station) | Great Northern to London King’s Cross | About 50 minutes, with trains roughly every 20 minutes |
| Stevenage (Stevenage Bioscience Catalyst) | Great Northern, Thameslink or LNER to London King’s Cross | About 25 minutes |
| Oxford | GWR to London Paddington | About 52 minutes |
| Oxford | Chiltern Railways to London Marylebone | 1 hour 9 minutes fastest, 1 hour 26 minutes on average |
| Harwell Campus | GWR from Didcot Parkway to London Paddington | About 36 minutes |
These are the fastest timetabled services. Average journeys run longer (Great Northern quotes about 1 hour 6 minutes on average from Cambridge), so add the hop across London from the terminus and check live times for your train.
The region already supplies much of the technology a biomarker team buys. A few public examples show the range of segments, and the kind of company that fits Stream 2.
Illumina’s European headquarters is at Granta Park, south of Cambridge. Oxford Nanopore is headquartered at the Oxford Science Park and has a presence on Harwell Campus. biomodal, the former Cambridge Epigenetix, develops multiomic sequencing that reads genetic and epigenetic information from one sample, at Chesterford Research Park.
Abcam, now part of Danaher, runs its global headquarters from the Cambridge Biomedical Campus and describes itself as a proteomics company. At Babraham Research Campus, Tagomics is building a multiomic biomarker platform, and Novogene chose the campus for its first European genomic sequencing centre.
Dysplasia Diagnostics, at Babraham, works on RNA blood profiling for cancer. Domainex offers integrated drug discovery services from Chesterford Research Park.
Stevenage Bioscience Catalyst sits beside GSK and hosts the Cell and Gene Therapy Catapult, with a strong cell and gene therapy focus. Harwell Campus describes a growing health tech cluster around the Rosalind Franklin Institute and the MRC Harwell Institute. These companies are named as examples of the cluster’s segments, not as ImmunoMark sponsors or delegates.
Sequencing, proteomics, spatial and diagnostics companies will usually choose Stream 2. Cell therapy analytics suppliers from the Stevenage side may also look at Stream 1. Each session below is quoted from the London 2027 agenda.
| If your company sells… | The London session that sets up the conversation |
|---|---|
| Sequencing, long-read or epigenetic assays | Day 2 · Stream 2: Keynote – Emerging Predictive & Prognostic Biomarkers in IO |
| Spatial biology and digital pathology | Day 1 · Stream 2: Digital Pathology & Spatial Transcriptomics in Oncology |
| Proteomics, antibody reagents and multiplex panels | Day 2 · Stream 2: Multiplex & Programmable Biomarker Platforms |
| Diagnostic tests and CDx development | Day 2 · Stream 2: Companion Diagnostics Co-development Strategies; Panel: Global CDx Approval Pathways – EMA, FDA & MHRA Perspectives |
| Assay development and lab services (CRO) | Day 1 · Stream 2: Biomarker Validation Strategies for Clinical Trial Success |
| Bioinformatics and biomarker data platforms | Day 2 · Stream 2: Real-World Evidence Integration into Biomarker Strategy |
| Immune monitoring for cell therapy trials | Day 1 · Stream 1: Clinical Trial Design in Immunotherapy: Adaptive & Biomarker-Driven Models; Day 2 · Stream 2: Functional T cell Biomarkers for Precision Immuno-Oncology |
The MHRA appears alongside the EMA and FDA in the Day 2 CDx panel, which matters to a UK diagnostics company planning a submission. For a deeper view of the CDx angle, see the companion diagnostics conference London page; discovery-stage spatial and single-cell vendors may prefer the oncology biomarker conference UK page.
Year ends differ across the cluster, so check where early March falls in your own financial year. With a December year end, the event lands early in a new budget and the decision is usually made in the autumn plan. With a March year end, it falls in the closing weeks of the old budget, so it is worth agreeing which year carries the cost before you commit.
On the regional calendar, One Nucleus, the Cambridge-headquartered life sciences membership organisation, holds its Genesis conference in London on 10 December 2026. That is a natural point to finalise a first-quarter event plan, with ImmunoMark London following about twelve weeks later. Our Golden Triangle life sciences events guide lists the wider regional calendar, and the London biotech events guide covers the capital.
Short travel means you can put more people in more meetings. Three packages cover most Golden Triangle companies.
For a platform company that wants stage time and a full meeting diary.
For assay, CRO and lab-services teams who sell through technical conversations.
For instrument and kit companies who want a stand for demos across both days.
Headline, Gold, Silver and Branding packages are also available. Full contents are on the London sponsorship opportunities page, and the sponsorship ROI calculator lets you test each one against your own deal size. For how other sponsors used the format, read our case studies.
Tell us where your team is based and what you sell, and we will suggest the Stream 2 package that fits.
Request the prospectusPick a package, add your own numbers and see the pipeline it creates. London 2026 sponsors averaged 15 to 25 meetings each, with 70% senior decision-makers in the room.
1. Choose a package
2. Your numbers
Year-one value of a new pharma or biotech customer
Booth visits, networking and questions after your talk
Share of conversations worth a proposal
Your typical close rate
Sponsorship plus travel and team costs
expected first-year revenue for every £1 of your event budget
Estimates only, based on the numbers you enter. Meetings and inclusions from the London 2027 sponsorship prospectus. 1:1 meetings are pre-scheduled with delegates you choose from the attendee list.
We will send your numbers to your inbox, ready to share with your team. Our sponsorship team gets a copy so they can answer questions.
The real London 2026 results, plus profiles of how different types of company use the 1:1 meetings, talks and stand to build pipeline.
What sponsors said
Here is what sponsors told us at our London 2026 launch edition.
We really liked the focus of the event, the topics, the talks, really good opportunity to engage with people, the support we get from you is really great and we appreciate that very much. Based on our experience we would be very interested in also sponsoring the next annual event.

We are always interested in sponsoring interesting conference, based on this years experience, I guess I will manage to get some budget for the next edition.

Conversations I have had are very high level, the footfalls been great and the kind of research going on around is really life changing. We will be very interested in sponsoring the second annual.

My experience here at Immunomark 2026 has been really great. We benefit from very good logistical organisation. Networking sessions were excellent and we consider Immunomark a strategic conference for the coming years.

We got the occasion to discuss customer projects and understand their needs better and how we can help them.

The conference has been great so far with strong interactions at the booth and excellent attendance at our talk. We will definitely think about the next edition.

Quality of the talks were really nice and the attendee list had experts from biotech pharma field. It was great meeting everyone and we look forward to positive outcomes.

The talks have been really interesting so far with a great combination of researchers and clinicians. Moderators encouraged excellent discussions.

Yes, for most teams. The fastest Great Northern trains from Cambridge to London King's Cross take about 50 minutes, GWR from Oxford to Paddington about 52 minutes, and Stevenage to King's Cross about 25 minutes. Day 1 opens with breakfast networking at 08:00 and ends with the drinks reception at 18:15; Day 2 closes at 16:30. Check live times for your train and allow for the journey across London.
Usually Stream 2, Biomarkers & Companion Diagnostics. Its London 2027 sessions include Digital Pathology & Spatial Transcriptomics in Oncology, Multiplex & Programmable Biomarker Platforms and Biomarker Validation Strategies for Clinical Trial Success. Cell therapy analytics suppliers may also look at Stream 1.
Yes. Day 2 of Stream 2 includes Panel: Global CDx Approval Pathways – EMA, FDA & MHRA Perspectives, followed later that afternoon by Companion Diagnostics Co-development Strategies.
Passes depend on the package: Platinum includes 8 team and 8 client passes, Gold 6 + 6, Silver 4 + 4 and Exhibitor 2 + 2. The Exclusive 1:1 Meetings package includes 2–4 passes plus drinks reception passes. Because the journey is short, many regional teams split the two days between application scientists and commercial staff; tell us your plan and we will confirm how passes can be used.
About 10 days before the event you receive the full delegate list with profiles, choose who you want to meet and flag priorities with the wishlist feature. Meetings are pre-scheduled 20-minute slots. Headline, Platinum and Gold include meetings, and the Exclusive 1:1 Meetings package offers 3, 5, 7 or 10.
Tell us who you want to meet. We will send the prospectus and a package recommendation within one working day.